CARDINAL HEALTH INC (CAH): Results of Operations and Financial Condition
CARDINAL HEALTH INC (CAH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a26q4_x063026xex991xnewsre.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance • Fourth quarter revenue increased 6% to $63.7 billion • Fourth quarter GAAP 1 d
How this was made
The 30-second read
Why it matters
The most tradable elements are the quantified FY2027 non-GAAP EPS range ($12.40 to $12.60, +13% to +15% growth) and the expanded $5.0B repurchase authorization, both of which can drive near-term valuation and positioning. The IEEPA tariff refund discussion is important for assessing earnings normalization and margin durability.
Market read
A company-specific earnings and guidance update with explicit EPS range and a larger buyback authorization is likely to be a primary driver of trading activity.
What to watch
The guidance is framed on non-GAAP metrics and includes interest and other expense headwinds; traders may focus on whether cash flow and segment profit growth can sustain the EPS range without tariff-related items.
Background
This is an SEC Form 8-K (Item 2.02) with Cardinal Health’s Q4 and full-year FY2026 results and its FY2027 non-GAAP EPS guidance, alongside capital return and credit facility updates.
Ticker impact
Cardinal Health reported FY2026 results and issued FY2027 non-GAAP EPS guidance of $12.40 to $12.60, plus $5.0B incremental buyback authorization.
Likely positive bias for the stock on guidance credibility and buyback optics, with upside/downside tied to how investors view the IEEPA tariff refund normalization.
The 8-K discloses specific FY2026 performance metrics, a quantified FY2027 EPS range, and a board-approved $5.0B increase to repurchase authorization, all of which are direct inputs to valuation and near-term positioning.
Market effects
Signals strength in pharmaceutical distribution and specialty services demand, potentially supporting sentiment across healthcare supply-chain peers.
Primarily US-listed large-cap healthcare services sentiment; limited direct regional spillover beyond US trading flows.
IEEPA tariff refund references suggest cross-border policy sensitivity, but the guidance is company-specific and US-traded.
Counterpoint
Investors may discount the guidance quality if FY2026 EPS benefited from one-time IEEPA tariff refund recognition, making normalized earnings less impressive.
Key entities
- companyCardinal Health
Reported Q4 and FY2026 results and provided FY2027 non-GAAP EPS guidance, plus incremental share repurchase authorization.
- customer/partnerKroger
Wholesaler distribution contract renewal is mentioned as a long-term renewal highlight.
- acquisition targetStrive Medical
Recently completed tuck-in acquisition referenced in FY2027 guidance assumptions.
- acquisition targetAdaptHealth
Announced tuck-in acquisition of its Diabetes Health business referenced in FY2027 guidance assumptions.
